Breakthrough T1d

About Breakthrough T1d

Breakthrough T1D’s recent portfolio is anchored by a $7.5 million award to the University of Massachusetts Medical School for beta cell replacement, a signal that the foundation prioritizes translational work aimed at replacing insulin-producing cells. Across its largest grants, the funder backs research institutions pursuing immune therapies, regeneration, complications, and clinical research, with multiple awards in the multimillion-dollar range. The pattern suggests a mission-driven portfolio built around type 1 diabetes rather than broad health funding. The foundation gives repeatedly to major academic medical centers and research organizations, including Harvard College, the University of Colorado, the University of Florida, and the University of California San Francisco. It also supports mission-adjacent infrastructure such as Tidepool and Civica Rx, alongside research centers and translational groups working on disease mechanisms and therapy development. Breakthrough T1D’s named programs reinforce that focus. Current opportunities include innovative awards, immune tolerance research for islet cell replacement, disease modeling using diabetes-on-a-chip platforms, ketone monitoring studies, vascularization strategies for durable islet replacement, and common-mechanism autoimmune research. The portfolio also includes conference support for scientific meetings tied to its mission.

What Breakthrough T1d Funds

Beta cell replacement is a clear priority. Breakthrough T1D gave $7,498,644 to the University of Massachusetts Medical School for beta cell replacement, and another large award went to Harvard College for the same area. They also fund immunotherapy and immune-tolerance research. The Regents of the University of Colorado received $5,657,381 for immunotherapies, while the University of Florida received $3,886,548 for the same topic in an earlier year. The foundation supports beta cell regeneration and related translational work as well. Beckman Research Institute of the City of Hope received $2,559,923 for beta cell regeneration, and the University of Miami later received $1,848,968 for that topic. Beyond core therapy development, Breakthrough T1D funds psychosocial support and complications research. Avera Mckennan received $2,480,110 and $1,520,870 for psychosocial work, while the Regents of the University of Michigan received $2,239,313 for complications.

How Breakthrough T1d Gives